Across TCGA pan-cancer cohorts, NKX2-5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NKX2-5 data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher NKX2-5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NKX2-5 expression acts as an unfavorable survival marker.
HNSC, SCLC, and BLCA are the cancer types where NKX2-5 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.